Dirk Heckl

This study identifies functional enhancer dependencies in pediatric AML using an integrative approach, revealing H-ME as an RNA-independent regulator of MYB.

This study identifies SNHG29 and IGF2BP1 as a lineage-specific oncogenic circuit in AMKL, showing their dependency and therapeutic vulnerability.

This study identifies DLK1 as a GATA1s-driven dependency in Down syndrome-associated myeloid leukemia, showing it as a therapeutic target with preclinical efficacy in PDX models.

This study identifies TRIP13 as a developmentally restricted dependency in NUP98::KDM5A+ pediatric AML, showing that its inhibition reactivates TP53 and kills leukemic cells.